These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

987 related articles for article (PubMed ID: 30946073)

  • 1. Surgery Improves Survival After Neoadjuvant Therapy for Borderline and Locally Advanced Pancreatic Cancer: A Single Institution Experience.
    Rangelova E; Wefer A; Persson S; Valente R; Tanaka K; Orsini N; Segersvärd R; Arnelo U; Del Chiaro M
    Ann Surg; 2021 Mar; 273(3):579-586. PubMed ID: 30946073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival in borderline resectable and locally advanced pancreatic cancer is determined by the duration and response of neoadjuvant therapy.
    Wijetunga AR; Chua TC; Nahm CB; Pavlakis N; Clarke S; Chan DL; Diakos C; Maloney S; Ashrafi-Zadeh A; Kneebone A; Hruby G; Jamieson NB; Gill A; Mittal A; Samra JS
    Eur J Surg Oncol; 2021 Oct; 47(10):2543-2550. PubMed ID: 33952409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer: An intention to treat analysis.
    Barenboim A; Lahat G; Geva R; Nachmany I; Nakache R; Goykhman Y; Brazowski E; Rosen G; Isakov O; Wolf I; Klausner JM; Lubezky N
    Eur J Surg Oncol; 2018 Oct; 44(10):1619-1623. PubMed ID: 30146251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant modified (m) FOLFIRINOX for locally advanced unresectable (LAPC) and borderline resectable (BRPC) adenocarcinoma of the pancreas.
    Blazer M; Wu C; Goldberg RM; Phillips G; Schmidt C; Muscarella P; Wuthrick E; Williams TM; Reardon J; Ellison EC; Bloomston M; Bekaii-Saab T
    Ann Surg Oncol; 2015 Apr; 22(4):1153-9. PubMed ID: 25358667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant-modified FOLFIRINOX vs nab-paclitaxel plus gemcitabine for borderline resectable or locally advanced pancreatic cancer patients who achieved surgical resection.
    Wolfe AR; Prabhakar D; Yildiz VO; Cloyd JM; Dillhoff M; Abushahin L; Alexandra Diaz D; Miller ED; Chen W; Frankel WL; Noonan A; Williams TM
    Cancer Med; 2020 Jul; 9(13):4711-4723. PubMed ID: 32415696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contemporary Management of Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer.
    Shaib WL; Ip A; Cardona K; Alese OB; Maithel SK; Kooby D; Landry J; El-Rayes BF
    Oncologist; 2016 Feb; 21(2):178-87. PubMed ID: 26834159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Characteristics of Patients Experiencing Pathologic Complete Response Following Neoadjuvant Therapy for Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma.
    Hashemi-Sadraei N; Gbolahan OB; Salfity H; O'Neil B; House MG; Shahda S
    Am J Clin Oncol; 2018 Oct; 41(10):982-985. PubMed ID: 28968257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FOLFIRINOX or Gemcitabine-based Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: A Multi-institutional, Patient-Level, Meta-analysis and Systematic Review.
    Eshmuminov D; Aminjonov B; Palm RF; Malleo G; Schmocker RK; Abdallah R; Yoo C; Shaib WL; Schneider MA; Rangelova E; Choi YJ; Kim H; Rose JB; Patel S; Wilson GC; Maloney S; Timmermann L; Sahora K; Rössler F; Lopez-Lopez V; Boyer E; Maggino L; Malinka T; Park JY; Katz MHG; Prakash L; Ahmad SA; Helton S; Jang JY; Hoffe SE; Salvia R; Taieb J; He J; Clavien PA; Held U; Lehmann K
    Ann Surg Oncol; 2023 Jul; 30(7):4417-4428. PubMed ID: 37020094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Respect - A multicenter retrospective study on preoperative chemotherapy in locally advanced and borderline resectable pancreatic cancer.
    Weniger M; Moir J; Damm M; Maggino L; Kordes M; Rosendahl J; Ceyhan GO; Schorn S;
    Pancreatology; 2020 Sep; 20(6):1131-1138. PubMed ID: 32739267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX.
    Michelakos T; Pergolini I; Castillo CF; Honselmann KC; Cai L; Deshpande V; Wo JY; Ryan DP; Allen JN; Blaszkowsky LS; Clark JW; Murphy JE; Nipp RD; Parikh A; Qadan M; Warshaw AL; Hong TS; Lillemoe KD; Ferrone CR
    Ann Surg; 2019 Apr; 269(4):733-740. PubMed ID: 29227344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma.
    Wagner M; Antunes C; Pietrasz D; Cassinotto C; Zappa M; Sa Cunha A; Lucidarme O; Bachet JB
    Eur Radiol; 2017 Jul; 27(7):3104-3116. PubMed ID: 27896469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis.
    Janssen QP; Buettner S; Suker M; Beumer BR; Addeo P; Bachellier P; Bahary N; Bekaii-Saab T; Bali MA; Besselink MG; Boone BA; Chau I; Clarke S; Dillhoff M; El-Rayes BF; Frakes JM; Grose D; Hosein PJ; Jamieson NB; Javed AA; Khan K; Kim KP; Kim SC; Kim SS; Ko AH; Lacy J; Margonis GA; McCarter MD; McKay CJ; Mellon EA; Moorcraft SY; Okada KI; Paniccia A; Parikh PJ; Peters NA; Rabl H; Samra J; Tinchon C; van Tienhoven G; van Veldhuisen E; Wang-Gillam A; Weiss MJ; Wilmink JW; Yamaue H; Homs MYV; van Eijck CHJ; Katz MHG; Groot Koerkamp B
    J Natl Cancer Inst; 2019 Aug; 111(8):782-794. PubMed ID: 31086963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Modified-FOLFIRINOX-Regimen-Based Neoadjuvant Therapy with Outcomes of Locally Advanced Pancreatic Cancer in Chinese Population.
    Li X; Guo C; Li Q; Wei S; Zhang Q; Chen Y; Shen Y; Ma T; Li G; Gao S; Que R; Lou J; Yu R; Yuan Y; Wei Q; Huang P; Liang T; Bai X
    Oncologist; 2019 Mar; 24(3):301-e93. PubMed ID: 30459238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic tumor burden as a prognostic indicator after neoadjuvant chemotherapy in pancreatic cancer.
    Lee W; Oh M; Kim JS; Sung M; Hong K; Kwak BJ; Park Y; Jun E; Song KB; Hwang DW; Lee JH; Yoo C; Kim KP; Park I; Jeong JH; Chang HM; Ryoo BY; Lee JB; Kim SC
    Int J Surg; 2024 Jul; 110(7):4074-4082. PubMed ID: 38537071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes of Primary Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma.
    Maggino L; Malleo G; Marchegiani G; Viviani E; Nessi C; Ciprani D; Esposito A; Landoni L; Casetti L; Tuveri M; Paiella S; Casciani F; Sereni E; Binco A; Bonamini D; Secchettin E; Auriemma A; Merz V; Simionato F; Zecchetto C; D'Onofrio M; Melisi D; Bassi C; Salvia R
    JAMA Surg; 2019 Oct; 154(10):932-942. PubMed ID: 31339530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma.
    Mellon EA; Hoffe SE; Springett GM; Frakes JM; Strom TJ; Hodul PJ; Malafa MP; Chuong MD; Shridhar R
    Acta Oncol; 2015 Jul; 54(7):979-85. PubMed ID: 25734581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Continued adjuvant FOLFIRINOX for BRPC or LAPC after neoadjuvant FOLFIRINOX.
    Park J; Kim HY; Na HY; Lee JS; Lee JC; Kim JW; Yoon YS; Hwang JH; Han HS; Kim J
    J Cancer Res Clin Oncol; 2023 May; 149(5):1765-1775. PubMed ID: 35723728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FOLFIRINOX-based neoadjuvant chemoradiotherapy for borderline and locally advanced pancreatic cancer: A pilot study from a tertiary centre.
    Pouypoudat C; Buscail E; Cossin S; Cassinotto C; Terrebonne E; Blanc JF; Smith D; Marty M; Dupin C; Laurent C; Dabernat S; Chiche L; Vendrely V
    Dig Liver Dis; 2019 Jul; 51(7):1043-1049. PubMed ID: 31000479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Neoadjuvant Therapy in Resected Pancreatic Ductal Adenocarcinoma of the Pancreatic Body or Tail on Surgical and Oncological Outcome: A Propensity-Score Matched Multicenter Study.
    Lof S; Korrel M; van Hilst J; Alseidi A; Balzano G; Boggi U; Butturini G; Casadei R; Dokmak S; Edwin B; Falconi M; Keck T; Malleo G; de Pastena M; Tomazic A; Wilmink H; Zerbi A; Besselink MG; Abu Hilal M;
    Ann Surg Oncol; 2020 Jun; 27(6):1986-1996. PubMed ID: 31848815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multi-agent neoadjuvant chemotherapy improves survival in early-stage pancreatic cancer: A National Cancer Database analysis.
    Deng A; Wang C; Cohen SJ; Winter JM; Posey J; Yeo C; Basu Mallick A
    Eur J Cancer; 2021 Apr; 147():17-28. PubMed ID: 33607382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 50.